Non-Alcoholic Fatty Liver Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with a liver condition called NAFLD (fat buildup in the liver not caused by alcohol), confirmed by a scan or imaging test, with other causes of liver fat ruled out
- You do not drink more than 30g of alcohol per day (if male) or 20g per day (if female) — roughly 2–3 standard drinks
- You have been found to have significant liver scarring (fibrosis) based on at least one non-invasive test, such as a FibroScan® or similar test
- You are 18 years old or older
- You are willing to have a liver biopsy (a small tissue sample taken from your liver)
- You agree to take part in the study and have signed a consent form after being fully informed
- You are covered by a social security or health insurance scheme (based in France)
Who may not be able to join:
- Your liver disease has reached an advanced stage with serious complications, such as signs of high blood pressure in the liver or liver failure
- Your liver condition is caused by something other than NAFLD, such as a viral infection (e.g. hepatitis), certain medications, excessive alcohol use, or a genetic condition
- You have any other type of liver disease, such as an autoimmune liver condition or hereditary iron overload (confirm with trial site for full list)
- You have been diagnosed with liver cancer at the time of joining the study
- You have a medical reason why a liver biopsy would not be safe for you, such as a blood clotting problem or a blockage in your bile ducts
- You are currently pregnant, have recently given birth, or are breastfeeding
- You are currently in prison or detained by a legal or government authority
- You are an adult who is under legal guardianship or has a legal protector managing your affairs
⚠️ Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 04.72.07.12.02
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The primary endpoint is the comparison of transcriptomic profiles between NAFL and NASH patients.; The primary endpoint is the secretome and single-cell phosphoproteome between NAFL and NASH patients.; The primary endpoint is the immunophenotyping of intrahepatic mononuclear cells between NAFL and NASH patients.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.